Graft Versus Host Disease (GVHD) Treatment Global Market Report 2024 by The Business Research Company | Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, A

The graft versus gost disease (GVHD) market size has grown strongly in recent years. It will grow from $2.65 billion in 2023 to $2.85 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increase in number of allogeneic transplantations, growing incidence of acute GVHD, increasing the rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, rising prevalence of GVHD worldwide, increase in chronic GVHD cases, advancements in technology, rise in patient population.

The graft versus gost disease (GVHD) market size is expected to see strong growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to Increase in the number of allogeneic transplantations, growing incidence of acute GVHD, increasing the rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, rising prevalence of GVHD worldwide, increase in chronic GVHD cases, advancements in technology, rise in the patient population. Major trends in the forecast period include partnerships, incetmnets, product approvals, and customizations.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=15579&type=smp

Graft Versus Host Disease (GVHD) Treatment Market Major Segments
The graft versus host disease (GVHD) treatment market covered in this report is segmented -

1) By Product Type: Corticosteroids, Monoclonal Antibodies, Immunosuppressants, Others
2) By Disease Type: Acute GvHD, Prophylaxis GvHD, Chronic GvHD
3) By End User: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

Key Driver - Rising Fungal Infection Rates Fueling Growth In The Candidiasis Therapeutics Market

The rising hematological disorders are expected to propel the growth of the graft versus host disease (GVHD) treatment market going forward. Hematological disorders, also known as blood disorders, encompass a wide range of conditions affecting the blood and its components, including red blood cells, white blood cells, platelets, and plasma. Hematological disorders is creating a wide space due to unhealthy lifestyle habits, genetic predisposition, and exposure to certain environmental toxins, such as radiation, chemicals, and pollutants. GVHD treatment strategies developed for managing GvHD can have broader implications for patients with hematological disorders, offering new avenues for immune modulation and improved disease management. For instance, in 2023, according to the Leukemia & Lymphoma Society, a US-based healthcare organization, Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 57,380 people in the US in 2023. This represents approximately 157 people each day or more than six people every hour die in the US from blood cancer. Therefore, the rising hematological disorders drive the graft versus host disease (GVHD) treatment market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=15579&type=smp

Prominent Trend - Driving Innovation in GVHD Treatment Market through Advanced Drug Development

Major companies operating in the graft versus host disease (GVHD) treatment market are developing advanced drugs and seeking their approval for the treatment of graft versus host disease (GVHD) treatment that gain a competetive edge in the market. Product approvals are critical for ensuring that healthcare products meet the necessary standards for safety, efficacy, and quality before they are made available to patients. For instance, in March 2023, Incyte corporation, a US-based healthcare company developed a ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, approved by the Food and Drug Administration, a US-based healthcare organization. These tablets were intended for once-daily use in treating specific types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).

Graft Versus Host Disease (GVHD) Treatment Market Players
Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/graft-versus-host-disease-gvhd-treatment-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the graft versus gost disease market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Graft Versus Host Disease (GVHD) Treatment Market Report Structure
3. Graft Versus Host Disease (GVHD) Treatment Market Trends And Strategies
4. Graft Versus Host Disease (GVHD) Treatment Market - Macro Economic Scenario
5. Graft Versus Host Disease (GVHD) Treatment Market Size And Growth
…..
27. Graft Versus Host Disease (GVHD) Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.